☆ 3.8 Article

Drug repurposing of Mito-Atovaquone for cancer treatment

PHARMACEUTICAL PATENT ANALYST (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers

Daniela Meco et al.

Summary: Repurposing approved non-antitumor drugs, such as Mebendazole, offers a promising and affordable strategy to increase the number of effective anticancer drugs. Mebendazole has demonstrated anticancer properties and can target multiple cancers. It shows potential as both a monotherapy and in combination with standard chemotherapeutics and radiotherapy. Its repurposing could reduce medical care costs and optimize existing cancer therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Oncology

Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials

Ignatios Ioakeim-Skoufa et al.

Summary: Drug repurposing, which explores the possibility of using existing marketed drugs in new therapeutic indications, has advantages over discovering new substances for medicinal use. This systematic review focuses on randomized controlled clinical trials that evaluate drug repurposing in cancer. It is important to carefully examine drug repurposing possibilities in oncology with well-designed trials, considering factors that could influence prognosis.

CANCERS (2023)

Add to Collection

Article Oncology

Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated

Alexandra McLean Stevens et al.

Summary: Novel well-tolerated agents are urgently needed to improve outcomes for children with acute myeloid leukemia. Atovaquone, an anti-infective agent, has both anti-leukemic and pneumonia-treating effects. In a clinical trial, atovaquone was well-tolerated during intensive chemotherapy but had lower plasma concentrations than expected, possibly due to side effects from chemotherapy. Correlative studies demonstrated anti-leukemia effects of atovaquone in patient samples and xenograft models, supporting further research on atovaquone and other agents for acute myeloid leukemia.

CANCERS (2023)

Add to Collection

Review Oncology

Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems

George Doumat et al.

Summary: Lung cancer, particularly NSCLC, remains a major health concern with low survival rates. The heterogeneity and plasticity of CSCs contribute to the high resistance of NSCLC to treatment. Drug repurposing offers a cost-effective strategy to develop new antineoplastic purposes for existing drugs.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation

Gang Cheng et al.

Summary: Glycolytic and mitochondrial oxidative metabolism are two major energy sources in tumors. Developing highly potent, nontoxic, and tumor-selective oxidative phosphorylation inhibitors may help advance therapeutic targeting of mitochondrial drugs in cancer. The newly developed PEGylated mitochondria-targeted ATO (Mito-(PEG)n-ATO) shows significant antiproliferative effects and synergistic effects when combined with other inhibitors in tumor cells.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone

Mofei Huang et al.

Summary: Mitochondria-targeted atovaquone inhibits the expression of genes involved in oxidative phosphorylation and glycolysis, leading to the death of granulocytic-myeloid-derived suppressor cells and regulatory T cells. This treatment also increases tumor-infiltrating CD4(+) T cells and improves the anti-tumor activity of PD-1 blockade immunotherapy.

ADVANCED SCIENCE (2022)

Add to Collection

Article Oncology

Atovaquone: An Inhibitor of Oxidative Phosphorylation as Studied in Gynecologic Cancers

Arvinder Kapur et al.

Summary: The Warburg effect, characterized by high glucose uptake and lactate release, is a hallmark of most cancers. Atovaquone, a mitochondrial complex III inhibitor, has been found to slow ovarian cancer growth and inhibit the proliferation of cancer stem cells both in vitro and in vivo. The drug is able to inhibit oxygen consumption and ATP production, and it alters several metabolic pathways. These findings provide mechanistic insights and preclinical data to support further investigation of atovaquone as a potential therapy for gynecologic cancers.

CANCERS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Discovery and mechanism studies of a novel ATG4B inhibitor Ebselen by drug repurposing and its anti-colorectal cancer effects in mice

Huazhong Xie et al.

Summary: In this study, we discovered a potential ATG4B inhibitor, compound Ebselen, for colorectal cancer therapy. We confirmed the covalent binding of Ebselen to ATG4B and identified the importance of Cys292 and Cys361 in the activity regulation of ATG4B. Cell culture and animal experiments further demonstrated the impact of Ebselen on autophagy and tumor suppression through ATG4B inhibition.

CELL AND BIOSCIENCE (2022)

Add to Collection

Article Parasitology

The effect of atovaquone on the mitochondrial membrane potential of Babesia gibsoni

Aiko Iguchi et al.

Summary: Atovaquone has a growth inhibitory effect on Babesia gibsoni by collapsing the mitochondrial membrane potential. The susceptibility to ATV may be affected by single nucleotide polymorphisms in mitochondria. ATV alone or in combination with proguanil can affect the mitochondrial membrane potential of B. gibsoni, with potential therapeutic implications.

EXPERIMENTAL PARASITOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study

Naiqi Zhang et al.

Summary: This study investigated whether the use of proguanil and atovaquone could reduce the risk of CRC in individuals with a family history of the disease, and found a significant negative association between proguanil/atovaquone use and CRC risk. Furthermore, there were significant dose- and duration-response correlations observed in the study.

BMC MEDICINE (2022)

Add to Collection

Article Oncology

Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer

Michael Skwarski et al.

Summary: This study presents the first clinical evidence that targeting tumor mitochondrial metabolism can reduce hypoxia and produce relevant antitumor effects at the mRNA level in NSCLC. Repurposing atovaquone for this purpose may improve treatment outcomes for NSCLC patients, as demonstrated by a significant reduction in hypoxic volume and downregulation of hypoxia-regulated genes in atovaquone-treated tumors. No atovaquone-related adverse events were reported, suggesting its potential as a safe and effective treatment option for NSCLC.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients

Pauline Bourigault et al.

Summary: Atovaquone reduces tumor hypoxia primarily in the inner and outer tumor subregions, with less effect in the center subregion. The most intensely hypoxic tumor voxels experienced the most significant decrease in hypoxia across different subregions. Atovaquone did not seem to have an impact on the edge subregion, which was non-hypoxic at baseline.

EJNMMI RESEARCH (2021)

Add to Collection

Article Pathology

Atovaquone at clinically relevant concentration overcomes chemoresistance in ovarian cancer via inhibiting mitochondrial respiration

Yue Guo et al.

Summary: Atovaquone, an antimicrobial drug, has shown potential in inhibiting ovarian cancer cells by disrupting mitochondrial function. It can effectively suppress the growth of ovarian cancer cells and induce apoptosis, while showing minimal effects on normal cells. Studies suggest that Atovaquone could be a promising candidate for the treatment of ovarian cancer, especially in combination with cisplatin.

PATHOLOGY RESEARCH AND PRACTICE (2021)

Add to Collection

Article Chemistry, Medicinal

Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis

Nehal Gupta et al.

Summary: Atovaquone shows anti-metastatic effects on triple-negative breast cancer by inducing apoptosis and reducing the expression of genes related to metastatic potential. In vivo experiments demonstrate that atovaquone significantly suppresses the growth of metastatic tumors in the lungs, liver, and brain, suggesting its potential as a treatment for breast cancer metastasis.

PHARMACEUTICALS (2021)

Add to Collection

Review Infectious Diseases

Management strategies for human babesiosis

Robert P. Smith et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone

Gang Cheng et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Medicine, Research & Experimental

Efficacy of atovaquone on EpCAM+CD44+ HCT-116 human colon cancer stem cells under hypoxia

Changhao Fu et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)

Add to Collection

Article Oncology

Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling

Nehal Gupta et al.

MOLECULAR CANCER THERAPEUTICS (2019)

Add to Collection

Article Hematology

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation

Alexandra M. Stevens et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Biochemistry & Molecular Biology

The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition

Feng Ke et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy

Dehong Chen et al.

JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2018)

Add to Collection

Article Biophysics

Atovaquone enhances doxorubicin's efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer

Zhuo Lv et al.

JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2018)

Add to Collection

Article Oncology

Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells

Subhadip Das et al.

LEUKEMIA RESEARCH (2018)

Add to Collection

Article Medicine, General & Internal

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Vinay Prasad et al.

JAMA INTERNAL MEDICINE (2017)

Add to Collection

News Item Multidisciplinary Sciences

New tricks for old drugs

Nicola Nosengo

NATURE (2016)

Add to Collection

Article Parasitology

Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex

Josephine E. Siregar et al.

PARASITOLOGY INTERNATIONAL (2015)

Add to Collection

Review Medicine, General & Internal

Drug repositioning: Re-investigating existing drugs for new therapeutic indications

B. M. Padhy et al.

JOURNAL OF POSTGRADUATE MEDICINE (2011)

Add to Collection

Article Microbiology

Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.:: Differential sensitivities to atovaquone

M Basselin et al.

EUKARYOTIC CELL (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.